Back
News
1 min de lecture

[Press Alert] XENOTHERA obtains authorization from ANSM to start the clinical trial of XAV19, its anti Covid treatment

  • contact@xenothera.com
  • Auteur
    contact@xenothera.com
  • Publié
    12 août 2020

Articles récents

[Press Information] Orphan designation by the European Medicines Agency for LIS1, the transplant induction therapy from XENOTHERA

July 11th, 2022. # Download our press information (english version) # Télécharger...

More

[Press Alert] Safety and efficacy results of LIS1

June 2022. # Download our press information (english version) # Télécharger notre...

More

[Press Information] XENOTHERA presents LIS1 results at the American Transplant Congress (ATC) in Boston

May 2022. # Download our press information (english version) # Télécharger notre...

More